Histamine antagonists promote cancer immunosurveillance.
cancer
cell death
immunotherapy
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
10
8
2023
pubmed:
9
8
2023
entrez:
9
8
2023
Statut:
epublish
Résumé
Recently, a cellular mini-immune system comprising infinitely expandable dendritic cells and T cells led to the discovery that histamine receptor H1 antagonists act on T cells to stimulate their proliferation and polarization toward a Th1/Tc1 phenotype and to increase their anticancer activity in the context of immunochemotherapy.
Identifiants
pubmed: 37554311
doi: 10.1080/2162402X.2023.2242211
pii: 2242211
pmc: PMC10405763
doi:
Substances chimiques
Histamine Antagonists
0
Histamine H1 Antagonists
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2242211Informations de copyright
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
OK is a cofounder of Samsara Therapeutics. GK has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Tollys and Vascage. GK has been consulting for Reithera. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. GK’s wife, Laurence Zitvogel, has held research contracts with 9 Meters Biopharma, Daiichi Sankyo, Pilege, was on the on the Board of Directors of Transgene, is a cofounder of everImmune and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. GK’s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim.
Références
Oncoimmunology. 2022 Jul 4;11(1):2096363
pubmed: 35800158
Oncoimmunology. 2019 Jul 18;8(11):e1638212
pubmed: 31646087
J Immunother Cancer. 2023 Jul;11(7):
pubmed: 37419511
Cancer Discov. 2021 Feb;11(2):408-423
pubmed: 33046534
J Natl Cancer Inst. 2020 Sep 1;112(9):964-967
pubmed: 31688928
Transl Oncol. 2021 Apr;14(4):101029
pubmed: 33550204
Nat Immunol. 2022 Apr;23(4):487-500
pubmed: 35145297
STAR Protoc. 2021 Aug 12;2(3):100732
pubmed: 34430908
Cancer Cell. 2022 Jan 10;40(1):36-52.e9
pubmed: 34822775
Nat Med. 2023 Jun;29(6):1310-1312
pubmed: 37193799
Int Rev Cell Mol Biol. 2022;370:33-64
pubmed: 35798506